Morgan Stanley reiterates ‘Equal-weight’ on Lupin Limited after strong Q3FY26 led by US and emerging markets. Revenue rose 24% Year-on-Year, with highest-ever US sales and robust analyst sentiment.
Morgan Stanley reiterates ‘Equal-weight’ on Lupin Limited after strong Q3FY26 led by US and emerging markets. Revenue rose 24% Year-on-Year, with highest-ever US sales and robust analyst sentiment.